Bio-Rad Laboratories, Inc. (BIO.B) stock
BIO.BNYSELaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BIO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 8/3055% above fair value
$379.50+0.00 (0.00%)
Close on Oct 29, 2026Market cap $10.18BP/E 46.2Yield –
Bio-Rad Laboratories EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Bio-Rad Laboratories's EPS for the twelve months ending Jun 30, 2026 was $8.25, down 29.7% year over year. For fiscal 2025 it was $27.85. Over ten years it grew 22.3% a year on average. The highest annual figure on record is $140.83 in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.85 | – |
| FY2024 | Dec 31, 2024 | -$65.36 | – |
| FY2023 | Dec 31, 2023 | -$21.82 | – |
| FY2022 | Dec 31, 2022 | -$121.79 | -186.5% |
| FY2021 | Dec 31, 2021 | $140.83 | +11.4% |
| FY2020 | Dec 31, 2020 | $126.47 | +117.0% |
| FY2019 | Dec 31, 2019 | $58.27 | +381.6% |
| FY2018 | Dec 31, 2018 | $12.10 | +197.3% |
| FY2017 | Dec 31, 2017 | $4.07 | +362.5% |
| FY2016 | Dec 31, 2016 | $0.88 | -76.3% |
| FY2015 | Dec 31, 2015 | $3.71 | +21.6% |
| FY2014 | Dec 31, 2014 | $3.05 | +13.4% |
| FY2013 | Dec 31, 2013 | $2.69 | -53.5% |
| FY2012 | Dec 31, 2012 | $5.78 | -8.1% |
| FY2011 | Dec 31, 2011 | $6.29 | -4.6% |
| FY2010 | Dec 31, 2010 | $6.59 | +26.7% |
| FY2009 | Dec 31, 2009 | $5.20 | +60.5% |
| FY2008 | Dec 31, 2008 | $3.24 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $13.85 | +18.7% |
| Q1 FY2026 | Mar 31, 2026 | -$19.55 | -953.7% |
| Q4 FY2025 | Dec 31, 2025 | $26.65 | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.70 | -154.4% |
| Q2 FY2025 | Jun 30, 2025 | $11.67 | – |
| Q1 FY2025 | Mar 31, 2025 | $2.29 | -83.0% |
| Q4 FY2024 | Dec 31, 2024 | -$25.57 | -310.6% |
| Q3 FY2024 | Sep 30, 2024 | $23.34 | +541.2% |
| Q2 FY2024 | Jun 30, 2024 | -$76.26 | – |
| Q1 FY2024 | Mar 31, 2024 | $13.45 | +479.7% |
| Q4 FY2023 | Dec 31, 2023 | $12.14 | -56.3% |
| Q3 FY2023 | Sep 30, 2023 | $3.64 | – |
| Q2 FY2023 | Jun 30, 2023 | -$39.59 | – |
| Q1 FY2023 | Mar 31, 2023 | $2.32 | – |
| Q4 FY2022 | Dec 31, 2022 | $27.78 | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.48 | -104.2% |
| Q2 FY2022 | Jun 30, 2022 | -$31.05 | -202.1% |
| Q1 FY2022 | Mar 31, 2022 | -$112.50 | -446.6% |
| Q4 FY2021 | Dec 31, 2021 | -$52.54 | -288.9% |
| Q3 FY2021 | Sep 30, 2021 | $130.02 | +197.9% |
| Q2 FY2021 | Jun 30, 2021 | $30.41 | -5.4% |
| Q1 FY2021 | Mar 31, 2021 | $32.46 | +42.9% |
| Q4 FY2020 | Dec 31, 2020 | $27.81 | +51.9% |
| Q3 FY2020 | Sep 30, 2020 | $43.64 | – |
| Q2 FY2020 | Jun 30, 2020 | $32.15 | +61.9% |
| Q1 FY2020 | Mar 31, 2020 | $22.72 | -20.9% |
| Q4 FY2019 | Dec 31, 2019 | $18.31 | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.68 | -197.6% |
| Q2 FY2019 | Jun 30, 2019 | $19.86 | +123.9% |
| Q1 FY2019 | Mar 31, 2019 | $28.74 | +32.0% |
| Q4 FY2018 | Dec 31, 2018 | -$27.73 | -1108.4% |
| Q3 FY2018 | Sep 30, 2018 | $8.89 | +1117.8% |
| Q2 FY2018 | Jun 30, 2018 | $8.87 | +5117.6% |
| Q1 FY2018 | Mar 31, 2018 | $21.77 | +5209.8% |
| Q4 FY2017 | Dec 31, 2017 | $2.75 | – |
| Q3 FY2017 | Sep 30, 2017 | $0.73 | +25.9% |
| Q2 FY2017 | Jun 30, 2017 | $0.17 | – |
| Q1 FY2017 | Mar 31, 2017 | $0.41 | – |
| Q4 FY2016 | Dec 31, 2016 | -$0.63 | – |
| Q3 FY2016 | Sep 30, 2016 | $0.58 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics